FI3509595T3 - Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita - Google Patents
Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita Download PDFInfo
- Publication number
- FI3509595T3 FI3509595T3 FIEP17849400.1T FI17849400T FI3509595T3 FI 3509595 T3 FI3509595 T3 FI 3509595T3 FI 17849400 T FI17849400 T FI 17849400T FI 3509595 T3 FI3509595 T3 FI 3509595T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- present
- amount
- hopo
- chelating agent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 5
- 229910052768 actinide Inorganic materials 0.000 title 1
- 150000001255 actinides Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229910052747 lanthanoid Inorganic materials 0.000 title 1
- 150000002602 lanthanoids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000002738 chelating agent Substances 0.000 claims 13
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384087P | 2016-09-06 | 2016-09-06 | |
| PCT/US2017/050121 WO2018048812A1 (en) | 2016-09-06 | 2017-09-05 | Formulations of hydroxypyridonate actinide/lanthanide decorporation agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3509595T3 true FI3509595T3 (fi) | 2023-03-01 |
Family
ID=61562894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17849400.1T FI3509595T3 (fi) | 2016-09-06 | 2017-09-05 | Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11684614B2 (enExample) |
| EP (1) | EP3509595B1 (enExample) |
| JP (3) | JP7018210B2 (enExample) |
| CA (1) | CA3035966A1 (enExample) |
| DK (1) | DK3509595T3 (enExample) |
| FI (1) | FI3509595T3 (enExample) |
| WO (1) | WO2018048812A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10982136B2 (en) | 2016-02-26 | 2021-04-20 | The Regents Of The University Of California | Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters |
| US11235076B2 (en) | 2016-08-29 | 2022-02-01 | Fred Hutchinson Cancer Research Center | Chelating platform for delivery of radionuclides |
| DK3509595T3 (da) | 2016-09-06 | 2023-01-23 | Univ California | Formuleringer af hydroxypyridonat-actinid/lanthanid-dekorporeringsmidler |
| EP3519034A4 (en) | 2016-09-29 | 2021-02-17 | The Regents of The University of California | CHELATING MOLECULES |
| WO2018097871A2 (en) | 2016-09-29 | 2018-05-31 | The Regents Of The University Of California | Separation of metal ions by liquid-liquid extraction |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3323857A (en) | 1965-12-16 | 1967-06-06 | Donald J Bauer | Selective extraction and separation of lanthanides with a quaternary ammonium compound |
| US3634113A (en) | 1968-10-30 | 1972-01-11 | Larry L Fehrenbacher | Stabilized zirconium dioxide and hafnium dioxide compositions |
| US4025602A (en) | 1976-05-25 | 1977-05-24 | The United States Of America As Represented By The United States Energy Research And Development Administration | Recovery of transplutonium elements from nuclear reactor waste |
| US4278559A (en) | 1978-02-16 | 1981-07-14 | Electric Power Research Institute | Method for processing spent nuclear reactor fuel |
| US4698431A (en) | 1985-11-12 | 1987-10-06 | The United States Of America As Represented By The United States Department Of Energy | Hydroxypyridonate chelating agents |
| GB8602304D0 (en) | 1986-01-30 | 1986-03-05 | Dakubu S | Dihydropyridine condensation products |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| FR2694451B1 (fr) | 1992-07-29 | 1994-09-30 | Asulab Sa | Cellule photovoltaïque. |
| US5634901A (en) | 1992-11-02 | 1997-06-03 | Localmed, Inc. | Method of using a catheter sleeve |
| JPH07104096A (ja) | 1993-10-05 | 1995-04-21 | Japan Atom Energy Res Inst | 酸性溶液中のランタニド元素と超プルトニウム元素の溶媒抽出による相互分離法 |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| FR2748951B1 (fr) | 1996-05-24 | 1998-07-03 | Commissariat Energie Atomique | Procede de separation selective des actinides (iii) et lanthanides (iii) |
| US20020122752A1 (en) | 1998-11-05 | 2002-09-05 | Taylor Charles E. | Electro-kinetic air transporter-conditioner devices with interstitial electrode |
| FR2794032B1 (fr) | 1999-05-27 | 2002-06-14 | Univ Claude Bernard Lyon | Procede pour separer en milieu aqueux des lanthanides et/ou des actinides par complexation-nanofiltration, et nouveaux complexants mis en oeuvre dans ce procede |
| US6221476B1 (en) | 1999-06-11 | 2001-04-24 | Ibc Advanced Technologies, Inc. | Polymeric membranes functionalized with polyhydroxypyridinone ligands |
| US6846915B2 (en) | 2001-08-13 | 2005-01-25 | The Regents Of The University Of California | Hydroxypyridonate and hydroxypyrimidinone chelating agents |
| EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
| FR2880180B1 (fr) | 2004-12-29 | 2007-03-02 | Cogema | Perfectionnement du procede purex et ses utilisations |
| EP1752471B9 (en) | 2005-01-05 | 2009-04-15 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| PL3190106T3 (pl) * | 2005-04-04 | 2019-10-31 | Univ Florida | Polieterowe analogi desferitiocyny |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| FR2900159B1 (fr) | 2006-04-19 | 2008-06-13 | Commissariat Energie Atomique | Separation groupee des actinides a partir d'une phase aqueuse fortement acide |
| AU2007272604B2 (en) | 2006-07-10 | 2013-08-01 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
| JP4911538B2 (ja) | 2006-12-26 | 2012-04-04 | 独立行政法人日本原子力研究開発機構 | 酸素及び窒素原子が活性な官能基を持つハイブリットドナー型抽出剤による３価及び４価アクチノイドの３価ランタノイドからの選択的分離法 |
| WO2008100907A2 (en) | 2007-02-13 | 2008-08-21 | Board Of Supervisors Of Louisiana State University And Argricultural And Mechanical College | Fluoride-releasing compositions |
| TW200836315A (en) * | 2007-02-16 | 2008-09-01 | Richtek Techohnology Corp | Electronic package structure and method thereof |
| WO2009018332A1 (en) | 2007-08-01 | 2009-02-05 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand |
| US8475747B1 (en) | 2008-06-13 | 2013-07-02 | U.S. Department Of Energy | Processing fissile material mixtures containing zirconium and/or carbon |
| WO2010129962A2 (en) | 2009-05-08 | 2010-11-11 | The Regents Of The University Of California | Combination treatment of hydroxypyridonate actinide/lanthanide decorporation agents |
| US20100317117A1 (en) | 2009-06-16 | 2010-12-16 | Los Alamos National Security, Llc | Selective membrane extraction of radioactive analytes |
| US8933526B2 (en) | 2009-07-15 | 2015-01-13 | First Solar, Inc. | Nanostructured functional coatings and devices |
| US20120132277A1 (en) | 2010-11-30 | 2012-05-31 | General Electric Company | Photovoltaic device and method for making |
| FR2988222B1 (fr) | 2012-03-13 | 2016-06-24 | Commissariat Energie Atomique | Module photovoltaique comprenant des elements de conversion spectrale localises et procede de realisation |
| US9472694B2 (en) | 2012-04-23 | 2016-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for upconversion of light and devices incorporating same |
| US10010535B2 (en) | 2013-11-22 | 2018-07-03 | University Of Florida Research Foundation, Incorporated | Desferrithiocin analogs and uses thereof |
| AU2015369722A1 (en) | 2014-12-22 | 2017-08-03 | Lumiphore, Inc. | Functionalized linear ligands and complexes thereof |
| CN104825389B (zh) | 2015-04-10 | 2018-03-16 | 广东药学院 | 一种盐酸小檗碱自微乳制剂及其制备方法 |
| CN104998251A (zh) | 2015-07-08 | 2015-10-28 | 哈尔滨吉象隆生物技术有限公司 | 用于口服肠溶制剂制备的具有促肠吸收作用的利拉鲁肽盐 |
| WO2017105565A2 (en) | 2015-09-10 | 2017-06-22 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted pet imaging and methods of their use |
| US10982136B2 (en) | 2016-02-26 | 2021-04-20 | The Regents Of The University Of California | Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters |
| EP3452040B1 (en) | 2016-05-03 | 2024-04-03 | The Regents of The University of California | Formulations and treatments employing hydroxypyridonate actinide/lanthanide decorporation agents |
| DK3509595T3 (da) | 2016-09-06 | 2023-01-23 | Univ California | Formuleringer af hydroxypyridonat-actinid/lanthanid-dekorporeringsmidler |
| WO2018097871A2 (en) | 2016-09-29 | 2018-05-31 | The Regents Of The University Of California | Separation of metal ions by liquid-liquid extraction |
| EP3519034A4 (en) | 2016-09-29 | 2021-02-17 | The Regents of The University of California | CHELATING MOLECULES |
-
2017
- 2017-09-05 DK DK17849400.1T patent/DK3509595T3/da active
- 2017-09-05 WO PCT/US2017/050121 patent/WO2018048812A1/en not_active Ceased
- 2017-09-05 US US16/330,601 patent/US11684614B2/en active Active
- 2017-09-05 JP JP2019512761A patent/JP7018210B2/ja active Active
- 2017-09-05 CA CA3035966A patent/CA3035966A1/en active Pending
- 2017-09-05 EP EP17849400.1A patent/EP3509595B1/en active Active
- 2017-09-05 FI FIEP17849400.1T patent/FI3509595T3/fi active
-
2022
- 2022-01-24 JP JP2022008581A patent/JP7391403B2/ja active Active
- 2022-02-04 US US17/665,135 patent/US12268678B2/en active Active
-
2023
- 2023-11-15 JP JP2023194144A patent/JP7712699B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7018210B2 (ja) | 2022-02-10 |
| US20220152003A1 (en) | 2022-05-19 |
| JP7712699B2 (ja) | 2025-07-24 |
| US12268678B2 (en) | 2025-04-08 |
| WO2018048812A1 (en) | 2018-03-15 |
| US20210283115A1 (en) | 2021-09-16 |
| DK3509595T3 (da) | 2023-01-23 |
| JP2024012598A (ja) | 2024-01-30 |
| EP3509595B1 (en) | 2022-11-02 |
| US11684614B2 (en) | 2023-06-27 |
| EP3509595A4 (en) | 2020-04-22 |
| JP2019532040A (ja) | 2019-11-07 |
| CA3035966A1 (en) | 2018-03-15 |
| JP2022044699A (ja) | 2022-03-17 |
| EP3509595A1 (en) | 2019-07-17 |
| JP7391403B2 (ja) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3509595T3 (fi) | Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| JP2015078230A5 (enExample) | ||
| FI3182975T3 (fi) | Rukaparibin suuren annosvahvuuden tabletteja | |
| HK1247822A1 (zh) | 用於活性剂口服给药的制剂 | |
| EA201400972A1 (ru) | Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения | |
| BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| NI201300054A (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| JP2015038135A5 (enExample) | ||
| SI2729130T1 (en) | Combined formulations of darunavir | |
| CY1122387T1 (el) | Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| WO2009120389A8 (en) | Oral and injectable formulations of tetracycline compounds | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| JP2015500340A5 (enExample) | ||
| JP2015129124A5 (enExample) | ||
| PH12014502170A1 (en) | Drug composition and soft capsule drug sealing the drug composition | |
| JP2012229264A5 (enExample) | ||
| RU2012100120A (ru) | Акарицидная фармацевтическая композиция на основе соли четвертичного фосфония, замещенного динитробензофураксана и ксимедонгидрохлорида | |
| TR200907915A2 (tr) | Kuru toz formunda farmasötik bileşim. | |
| UA102844U (uk) | Таблетка, що містить тетрагідрат dl-гідроаспарагінату магнію, напівгідрат dl-аспарагінату калію та сухий екстракт глоду криваво-червоного |